How Big Pharma Can Play To Win In US Biosimilars
This article was originally published in Scrip
Successful entry into the nascent US biosimilars market is fraught with unknowns, but an analysis by independent research service BioMedTracker concludes that aspiring big pharma would be well advised to partner early, ideally when the drug is in development outside the US, and to use the 351(k) abbreviated pathway to get the quickest regulatory approval.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.